Enzo Biochem, Inc. announced the launch of the AMPIVIEW(TM) line, a breakthrough RNA gene expression platform powered by Enzo's LoopRNA(TM) in situ hybridization technology. The AMPIVIEW(TM) platform with its first products for HPV detection and analysis significantly expands Enzo's position in the oncology market and paves the way for expansion into the growing spatial biology space. Enzo's AMPIVIEW(TM) RNA products combine the precision of targeted, sequence-specific probes with the superior sensitivity of its novel LoopRNA(TM) ISH technology.

This innovative design enables sensitive and specific detection of target genes in tissue or cell samples while preserving the morphology. The study of single cells within their native tissue environment, known as spatial biology, helps scientists better characterize and understand disease. This spatial biology market is expected to reach $2.15B in 2030(1) with a compound annual growth rate (CAGR) of 13.6%.

HPV testing is part of Enzo's focus on women's health and oncology and leverages the Company's long history in HPV detection while complementing the existing offering of Enzo's POLYVIEW(R) immunohistochemistry ("IHC") and PATHO-GENE(R) in situ hybridization ("ISH") detection platforms, an enhanced diagnostic detection system used by pathologists in reading tissue biopsies. Applying this powerful AMPIVIEW(TM) visualization technology to HPV analysis is a logical extension of Enzo's already broad portfolio of tissue analysis assays and reagents.